Westwood Holdings Group Inc. Has $12.03 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westwood Holdings Group Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,503 shares of the biopharmaceutical company’s stock after selling 266 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,034,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $932,571,000. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $339,594,000. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after acquiring an additional 195,902 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $10.95 during trading hours on Friday, hitting $1,082.19. 646,247 shares of the stock were exchanged, compared to its average volume of 415,793. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. The company has a market cap of $119.25 billion, a PE ratio of 31.97, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13. The company’s fifty day simple moving average is $1,043.43 and its two-hundred day simple moving average is $982.47. Regeneron Pharmaceuticals, Inc. has a 1-year low of $759.15 and a 1-year high of $1,115.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday. Finally, TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,097.05.

Insider Activity

In other news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,074 shares of company stock valued at $64,546,123. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.